Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Class A Ordinary Shares, par value $0.0001 per share
-
Shares outstanding
-
424,966,351
-
Total 13F shares
-
310,848,061
-
Share change
-
+3,084,147
-
Total reported value
-
$8,731,929,890
-
Put/Call ratio
-
70%
-
Price per share
-
$28.09
-
Number of holders
-
359
-
Value change
-
+$90,598,401
-
Number of buys
-
205
-
Number of sells
-
139
Institutional Holders of Royalty Pharma plc - Class A Ordinary Shares, par value $0.0001 per share (RPRX) as of Q4 2023
As of 31 Dec 2023,
Royalty Pharma plc - Class A Ordinary Shares, par value $0.0001 per share (RPRX) was held by
359 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
310,848,061 shares.
The largest 10 holders included
MORGAN STANLEY, VANGUARD GROUP INC, FMR LLC, BlackRock Inc., BAILLIE GIFFORD & CO, ADAGE CAPITAL PARTNERS GP, L.L.C., VIKING GLOBAL INVESTORS LP, STATE STREET CORP, JPMORGAN CHASE & CO, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
359
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.